Roche’s Tecentriq + Avastin Receive FDA’s Breakthrough Designation as 1L Treatment for Advanced or Metastatic Hepatocellular Carcinoma (HCC)

 Roche’s Tecentriq + Avastin Receive FDA’s Breakthrough Designation as 1L Treatment for Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Roche Presents New P-III Data of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020

Shots:

  • The FDA’s BT designation is based on P-Ib (NCT02715531) study assessing Tecentriq (1200mg) + Avastin (15 mg/kg) in 23 patients with advanced or metastatic first-line HCC
  • The P-Ib study results: median follow-up of 10.3 mos. as per RECIST v1.1 (65%); response rate (61%); PFS, DOR, TTP, & OS not reached follow up of 10.3 mos.; no new safety signals
  • Tecentriq (atezolizumab) + Avastin (bevacizumab) is a combination therapy, Tecentriq inhibit VEGF to restores anti-cancer immunity & Avastin shows anti-angiogenic effects enhancing the effect of Tecentriq

Click here to read full press release/ article | Ref: Roche | Image: PM Live

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post